The Effect of Virtual Reality Application Used During Endoscopy on Pain, Anxiety and Vital Signs: A Mixed Methods Study
Launched by İBRAHİM NAS · Oct 18, 2022
Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study looks at whether using virtual reality (VR) glasses during an upper gastrointestinal endoscopy can reduce pain, anxiety, and small changes in vital signs (like heart rate and blood pressure). It is a randomized, parallel trial, meaning people are randomly assigned to either the VR group or a standard-care group, and both groups are followed at the same time. It also uses a qualitative part, asking some participants about their experiences, to provide a fuller picture. The study is taking place at Van Yüzüncü Yıl University in Turkey, and aims to enroll about 80 adults who are having a diagnostic endoscopy.
If you’re invited to participate, you’d be randomly placed in one of two groups. In the VR group, you’d wear VR glasses from before the procedure until it ends, with the option to stop anytime. You’d complete short questionnaires about anxiety and pain before and after the endoscopy, and your vital signs (like heart rate, blood pressure, breathing rate, temperature, and oxygen levels) would be checked around the time of the procedure. The control group would receive the usual care without VR. Two hours after the procedure you’d share your general thoughts about the experience, and a follow-up interview would occur later for the qualitative part. To be eligible, you’d need to be 18 or older, able to read and write Turkish, have no mental or sensory problems, be undergoing a diagnostic endoscopy, not have sedation planned, and not have taken pain medicines in the last 8 hours; those who need sedation or are taking analgesics around the procedure would be excluded. At the moment, results from the trial have not yet been reported.
Gender
ALL
Eligibility criteria
- Criteria:
- Inclusion criteria:
- • Inclusion criteria for the quantitative study;
- • 18 years and older,
- • who can read and write Turkish,
- • without mental problems,
- • Having no vision, hearing or perception problems,
- • Diagnostic endoscopy was performed,
- • No sedation before and during the procedure
- • who volunteered to participate in the study,
- • Those who have not taken analgesics in the last 8 hours
- • Qualitative research inclusion criteria;
- • in the experimental group,
- • who volunteered to participate in the research
- Exclusion Criteria:
- • Exclusion criteria from quantitative section research;
- • sedation applied,
- • who want to withdraw from the study,
- • Patients using analgesics or anti-anxiety medications before and during the procedure
- • Exclusion criteria from qualitative departmental research;
- • • Those in the control group
About İbrahi̇m Nas
İbrahim Nas is a distinguished clinical trial sponsor recognized for its commitment to advancing medical research and innovation. With a focus on developing cutting-edge therapies and treatments, the organization collaborates with leading researchers and institutions to design and implement robust clinical studies. İbrahim Nas prioritizes patient safety and ethical standards, ensuring that all trials adhere to rigorous regulatory guidelines. Through its dedication to scientific excellence and a patient-centered approach, İbrahim Nas aims to contribute significantly to the enhancement of healthcare outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Van, Turkey
Patients applied
Trial Officials
GÜLAY İPEK ÇOBAN, Prof.Dr.
Principal Investigator
Ataturk University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials